Rabies vaccines: where do we stand, where are we heading?

Expert Rev Vaccines. 2015 Mar;14(3):369-81. doi: 10.1586/14760584.2015.973403. Epub 2014 Oct 28.

Abstract

Rabies being the most lethal zoonotic, vaccine-preventable viral disease with worldwide distribution of reservoir wild animals presents unique challenges for its diagnosis, management and control. Although vaccines available are highly effective, which had played the key role in controlling rabies in North America, western Europe and in a number of Asian and Latin American countries, the requirement of multiple doses along with boosters, associated cost to reduce the incidence in wild animals and prophylactic human vaccination has remained a major impediment towards achieving the same goals in poorer parts of the world such as sub-Saharan Africa and southeast Asia. Current efforts to contain rabies worldwide are directed towards the development of more safe, cheaper and efficacious vaccines along with anti-rabies antibodies for post-exposure prophylaxis. The work presented here provides an overview of the advances made towards controlling the human rabies, particularly in last 10 years, and future perspective.

Keywords: encephalitis; glycoprotein; in vivo challenge; protection; rabies virus-neutralizing antibody; survival; therapeutics; vaccines.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Drug Discovery / trends
  • Global Health
  • Humans
  • Rabies / epidemiology*
  • Rabies / prevention & control*
  • Rabies Vaccines / immunology*
  • Rabies Vaccines / isolation & purification*
  • Vaccination / economics
  • Vaccination / methods*

Substances

  • Rabies Vaccines